116 related articles for article (PubMed ID: 33970459)
1. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
2. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
3. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
5. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
6. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y
Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064
[No Abstract] [Full Text] [Related]
8. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Tabassum N; Zhang H; Stebbing J
Cell Rep Med; 2020 Nov; 1(8):100145. PubMed ID: 33225317
[TBL] [Abstract][Full Text] [Related]
9. Fostamatinib combined with TPO-RAs or steroids as a bridge to monotherapy or as time-limited continuous treatment in relapsed chronic ITP: A single-centre case series.
Passucci M; Laganà A; Donzelli L; Masucci C; Genoese A; Chistolini A; Baldacci E; Santoro C
Br J Haematol; 2024 May; 204(5):2129-2132. PubMed ID: 38563350
[No Abstract] [Full Text] [Related]
10. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
11. Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib.
Innao V; Calogero RD; Lo Presti F; Consoli U
Case Rep Hematol; 2023; 2023():9953245. PubMed ID: 37323813
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Matsukane R; Suetsugu K; Hirota T; Ieiri I
Clin Pharmacokinet; 2022 Jul; 61(7):955-972. PubMed ID: 35781630
[TBL] [Abstract][Full Text] [Related]
13. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K; Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series.
Liu J; Hsia CC
Adv Hematol; 2022; 2022():8119270. PubMed ID: 36393999
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials.
Ali MA; Anwar MY; Aiman W; Dhanesar G; Omar Z; Hamza M; Zafar M; Rengarajan HK; Maroules M
J Xenobiot; 2023 Jan; 13(1):29-41. PubMed ID: 36810430
[TBL] [Abstract][Full Text] [Related]
16. Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.
Flora A; Jepsen R; Pham J; Frew JW
J Invest Dermatol; 2024 Apr; 144(4):786-793.e1. PubMed ID: 37879397
[TBL] [Abstract][Full Text] [Related]
17. [Recent topics in the pathophysiology and treatment of immune thrombocytopenic purpura].
Kashiwagi H
Rinsho Ketsueki; 2023; 64(5):397-405. PubMed ID: 37271531
[TBL] [Abstract][Full Text] [Related]
18. Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.
Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F
Ther Adv Hematol; 2023; 14():20406207221147777. PubMed ID: 37426835
[TBL] [Abstract][Full Text] [Related]
19. Sustained response off therapy after fostamatinib: A chronic refractory ITP case report.
Auteri G; Biondo M; Mazzoni C; Venturi M; Romagnoli AD; Paglia S; Cavo M; Vianelli N; Palandri F
Heliyon; 2023 Feb; 9(2):e13462. PubMed ID: 36846652
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
Kuter DJ; Piatek C; Röth A; Siddiqui A; Numerof RP; Dummer W;
Am J Hematol; 2024 Jan; 99(1):79-87. PubMed ID: 37929318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
